Study of a new drug to treat rheumatoid arthritis

• Research type

  Research Study

• Full title

  A randomized, placebo-controlled, single-blind study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of intravenous otelixizumab in rheumatoid arthritis subjects

• IRAS ID

  32290

• Sponsor organisation

  GlaxoSmithKline R&D Ltd

• Eudract number

  2008-008206-40

• ISRCTN Number

  Not available

• Research summary

  N/A

• REC name

  North East - Tyne & Wear South Research Ethics Committee

• REC reference

  09/H0904/52

• Date of REC Opinion

  17 Nov 2009

• REC opinion

  Further Information Favourable Opinion